New data from the UNTOUCHED trial showed a low rate of inappropriate shocks with Boston Scientific Corp.’s Emblem subcutaneous implantable cardioverter defibrillator (S-ICD), providing further support for the Emblem S-ICD as an alternative to ICDs with transvenous leads for patients indicated for an ICD without a pacemaker.
Principal investigator Michael Gold of the Medical University of South Carolina in Charleston presented the 18-month UNTOUCHED results on 8 May, the same day they were scheduled to be presented...